Journavx for Pain Management: Toward Affordabil...

By Rene Pretorius

April 25, 2025

In this review I summarize the ICER 2025 evaluation report of suzetrigine (Journavx®), a new FDA-approved non-opioid oral analgesic. It targets the N...
Navigating Drug Price Regulation: Evaluating the Executive Order’s Pote...
Capivasertib Cost-Effectiveness in Advanced Breast Cancer
Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critic...
Toripalimab Evidence Journey in Cancer Care
NICE Breakthrough: Record Positive Recommendations for Blood Cancer Treatment...
Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, an...
Engineering Resilience: Mastering Pharma Patent Expiration Strategy
Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefit...
Journavx Market Access Strategy in Focus: What Early Payer Decisions Signal f...
Pharmacy Benefit Managers Report Reveals Escalating Drug Costs and Calls for ...
Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate
Access to Anti-Obesity Medication for Medicare and Medicaid